![](/img/cover-not-exists.png)
LB0005 12-week results of a phase 2B dose-ranging study of LY3009104 (INCB028050), an oral JAK1/JAK2 inhibitor, in combination with traditional dmards in patients with rheumatoid arthritis
Keystone, E., Taylor, P., Genovese, M., Schlichting, D., Beattie, S., Gaich, C., Fidelus Gort, R., Luchi, M., Macias, W. L.Volume:
71
Language:
english
Journal:
Annals of the Rheumatic Diseases
DOI:
10.1136/annrheumdis-2012-eular.1965
Date:
June, 2012
File:
PDF, 74 KB
english, 2012